# **OncoTargets and Therapy**

a Open Access Full Text Article

### CORRIGENDUM

# Downregulation of miR-575 Inhibits the Tumorigenesis of Gallbladder Cancer via Targeting P27 Kip1 [Corrigendum]

Qin Y, Mi W, Huang C, Li J, Zhang Y, Fu Y. Onco Targets Ther. 2020;13:3667-3676.

The authors apologize for this error and advise it does not affect the results of the paper.

The authors have advised due to an error at the time of figure assembly, Figure 1E on page 3670 is incorrect. The correct Figure 1 is shown below.



Figure 1 Downregulation of miR-575 significantly upregulated the proliferation of GBC cells. GBC-SD or G415 cells were transfected with miR-575 agonist, miR-575 antagonist, negative control (NC) or nothing (Blank) for 24 h. (A) The expression of miR-575 in GBC-SD or G415 cells was detected by using qRT-PCR. (B) After 0, 24, 48, or 72 h of incubation, the OD value of GBC-SD cells was determined using CCK-8 assay. (C) After 0, 24, 48, or 72 h of incubation, the OD value of G415 cells was determined using CCK-8 assay. (D) After 48 h of incubation, the expression of Ki-67 in GBC-SD cells was detected by immunofluorescence staining. The expression of Ki-67 in GBC-SD cells was quantified by integrated optical density (IOD). (E) After 48 h of incubation, the expression of Ki-67 in G415 cells was detected by immunofluorescence staining. The expression of Ki-67 in G415 cells was quantified by integrated optical density (IOD). Each group were performed at least three independent experiments. \*P<0.01 vs control group; \*\*P<0.01 vs control group;

permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For

submit your manuscript **Dove**Press f 🄰 in 🗖 http://doi.org/10.2147/OTT.S29422

OncoTargets and Therapy 2020:13 12365-12366 CO 0 S C2020 Qin et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php

OncoTargets and Therapy downloaded from https://www.dovepress.com/ For personal use only

#### **OncoTargets and Therapy**

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

# **Dove**press

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.